Q1 EPS Estimates for Globus Medical Reduced by Roth Capital

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Roth Capital cut their Q1 2025 earnings estimates for shares of Globus Medical in a research note issued to investors on Friday, February 21st. Roth Capital analyst J. Wittes now expects that the medical device company will earn $0.74 per share for the quarter, down from their prior forecast of $0.75. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Roth Capital also issued estimates for Globus Medical’s Q2 2025 earnings at $0.82 EPS, Q3 2025 earnings at $0.85 EPS, FY2025 earnings at $3.40 EPS, FY2026 earnings at $4.29 EPS and FY2027 earnings at $4.75 EPS.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, February 20th. The medical device company reported $0.84 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.10. The firm had revenue of $657.29 million for the quarter, compared to analyst estimates of $646.19 million. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%.

Several other research firms have also commented on GMED. StockNews.com raised shares of Globus Medical from a “hold” rating to a “buy” rating in a report on Friday, February 14th. Morgan Stanley raised shares of Globus Medical from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $83.00 to $100.00 in a report on Monday, December 2nd. BTIG Research increased their target price on shares of Globus Medical from $87.00 to $91.00 and gave the company a “buy” rating in a report on Thursday, December 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Globus Medical in a report on Friday, February 21st. Finally, Canaccord Genuity Group raised their price target on shares of Globus Medical from $92.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $97.82.

Globus Medical Stock Performance

GMED stock opened at $79.65 on Monday. Globus Medical has a 52 week low of $49.33 and a 52 week high of $94.93. The firm’s fifty day moving average is $86.61 and its 200 day moving average is $79.25. The firm has a market cap of $10.85 billion, a P/E ratio of 106.20, a P/E/G ratio of 1.61 and a beta of 1.19.

Insider Transactions at Globus Medical

In other news, SVP Kelly Huller sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $87.00, for a total value of $217,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Keith W. Pfeil sold 14,167 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $88.29, for a total transaction of $1,250,804.43. The disclosure for this sale can be found here. Corporate insiders own 18.54% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Oak Thistle LLC purchased a new position in Globus Medical during the 4th quarter valued at about $376,000. bLong Financial LLC purchased a new position in Globus Medical during the 4th quarter valued at about $397,000. Kathmere Capital Management LLC purchased a new position in Globus Medical during the 4th quarter valued at about $23,091,000. Quest Partners LLC purchased a new position in Globus Medical during the 3rd quarter valued at about $523,000. Finally, Intech Investment Management LLC lifted its position in Globus Medical by 291.3% during the 3rd quarter. Intech Investment Management LLC now owns 20,530 shares of the medical device company’s stock valued at $1,469,000 after acquiring an additional 15,283 shares during the period. 95.16% of the stock is owned by hedge funds and other institutional investors.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.